15 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
by their commitment to patients, their people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
s8nk 90mzteniqb4601ls0exjqqsde0k4px74fv5zxhp
TAK
16 May 24
, NYSE:TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered
piuqxtgjxrnmys9ax0tm
ACIU
TAK
13 May 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
ut2r8vm8tmpfk9muii2qlqyu4acsqi7f9i5
ACIU
TAK
13 May 24
of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered
ai2edd4x5qzibvk1rqqsy9vyy3dwxeyfkjajnnpz8js43enodbdcpkc
TAK
9 May 24
Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology
uud2qtqkmzrufkwngwyn6ubi3uem8ckvtp
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
i8104bk21d0bzmy8dy7ynzyctb5w00trhhmfdxa1lcqxoaolt7bxlxe
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
zcs88i1g qx9fddv1kne0kbta1gvx8rgwvx2qeuvyt86pn5k
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
9o2oegv9eis6ompdeh5bonfw1wj0psvt10an
TAK
27 Mar 24
: 4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical
czwrqnvbbpz ijx0z
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
rsskhuh3q1ergpmhovo6hvwvq b99d84siovxomts0hl
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
- Prev
- 1
- Next